Long COVID Infections and Infestations
Conditions
Interventions
1. Recruitment: Participants will be identified through primary care settings, by email through affiliated cohorts (UK PROTECT study and Covid Symptom Study Biobank), publicity and social media. All p
Sponsors
University of Exeter
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 23/09/2025: 1. Age 18 and over (primary analysis cohort: 50 and over) 2. Self-reported Covid-19 infection (based on previous positive PCT/LFT test, laboratory /hospital diagnosis or suspected infection) 3. Subjective Cognitive Impairment (based on self-report, supported by capture of symptoms and impacts) 4. Access to a smartphone, tablet or computer with an internet connection. 5. Ability to understand the English language sufficiently well to take part. _____ Previous inclusion criteria: 1. Age 18 years and over 2. Self-reported Covid-19 infection (based on previous positive PCT/LFT test, laboratory /hospital diagnosis or suspected infection) 3. Subjective Cognitive Impairment (based on self-report, supported by capture of symptoms and impacts) 4. Access to a smartphone, tablet or computer with an internet connection. 5. Ability to understand the English language sufficiently well to take part.
Exclusion criteria
Exclusion criteria: 1. Already taking part in another active interventional clinical trial 2. Having accessed the ReaCT programme online through participation in the PROTECT UK ageing cohort over the last 12 months 3. Diagnosis of dementia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 23/09/2025: Executive function measured using the well-validated verbal reasoning task at 6 months _____ Previous primary outcome measure: Executive function measured using the well-validated verbal reasoning task at 6 weeks and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline, 6 weeks and at 6 months: 1. Cognition measured using the FLAME cognitive test battery 2. Self-reported and Informant cognition measured by the IQCODE 3. Subjective cognitive impairment measured by the 24-item Subjective Cognitive Decline Questionnaire 4. Quality of life measured by the EQ5D measure with EQ-VAS 5. Instrumental Activities of Daily Living measured by a modified self and informant reported six-item IADL, based on the previous ReaCT trial, the Post-COVID Functional Status (PCFS) scale and the Washington Group Short Set on Functioning (WG-SS). 6. Symptoms of mood and depression, measured by the nine-item Patient Health Questionnaire (PHQ-9). 7. Symptoms of anxiety, measured by the seven-item Generalised Anxiety Disorder (GAD-7) scale. 8. Experience of fatigue measured by the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT) scale27. An additional question will capture the approximate time of day participants experience fatigue. 9. Sleep quality measured by the short-form Cognition Online Sleep Monitoring Scale (COSMOS) 10. Health care and personal social care service usage will be captured using a modified version of the Client Service Receipt Inventory (CSRI) 28 to enable health economics analysis. 11. Within the CSRI, participants will be asked to provide brief details about their employment activity to support the health economic analysis and to capture changes in their employment activity post-COVID infection. | — |
Countries
England, United Kingdom
Outcome results
None listed